Activation of Intracellular Complement in Lungs of Patients With Severe COVID-19 Disease Decreases T-Cell Activity in the Lungs
A novel coronavirus, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), arose late in 2019, with disease pathology ranging from asymptomatic to severe respiratory distress with multi-organ failure requiring mechanical ventilator support. It has been found that SARS-CoV-2 infection drives...
Main Authors: | Mark C. Howell, Ryan Green, Andrew R. McGill, Roukiah M. Kahlil, Rinku Dutta, Shyam S. Mohapatra, Subhra Mohapatra |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-11-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.700705/full |
Similar Items
-
SARS–CoV-2 Immuno-Pathogenesis and Potential for Diverse Vaccines and Therapies: Opportunities and Challenges
by: Andrew R. McGill, et al.
Published: (2021-02-01) -
SARS-CoV-2-Induced Gut Microbiome Dysbiosis: Implications for Colorectal Cancer
by: Mark C. Howell, et al.
Published: (2021-05-01) -
Combination Therapy of Mithramycin A and Immune Checkpoint Inhibitor for the Treatment of Colorectal Cancer in an Orthotopic Murine Model
by: Rinku Dutta, et al.
Published: (2021-07-01) -
Ultrafast-UV laser integrating cavity device for inactivation of SARS-CoV-2 and other viruses
by: Sharad Ambardar, et al.
Published: (2022-07-01) -
Acetate-encapsulated Linolenic Acid Liposomes Reduce SARS-CoV-2 and RSV Infection
by: Andrew R. McGill, et al.
Published: (2023-06-01)